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To the Editor: Chikungunya is a reemerging, mos-
quitoborne infectious disease caused by chikungunya vi-
rus (CHIKV). Its classic manifestations include fever and 
joint inflammation, which can develop into chronic joint 
disease. Infections in immunocompromised persons can 
lead to severe organ involvement and death. Chikungu-
nya outbreaks appear to occur in 2 patterns: 1) spatial-
ly and temporally restricted outbreaks in endemic areas 
(1,2); and 2) large epidemics that occur periodically every 
40–50 years affecting multiple geographic areas (3). The 
mechanisms associated with the initiation of these large 
outbreaks are not well understood. An A226V amino acid 
substitution in the virus envelope, which enhances repli-
cation in Aedes albopictus, a mosquito vector for CHIKV, 
and expansion of vectors into areas with previously im-
munologically naive populations are thought to be re-
sponsible for some recent epidemics (4). In chikungunya-
endemic areas, environmental factors such as changes 
in rainfall and vector densities have been implicated in 
smaller scale outbreaks. The mechanisms underlying out-
break resolution are not well understood. Herd immunity 
afforded by exposed persons might play an important role 
in preventing ongoing virus transmission. Reported sero-
prevalence rates in affected areas have ranged from 10% 
to ≈40% after an outbreak (5–7).
We established an age-structured prospective cohort 
consisting of persons >6 months of age in Cebu, Philippines, 
and conducted active surveillance for acute febrile illnesses 
by making weekly telephone calls or home visits during 
2012–2014 (Table). We defined symptomatic chikungunya 
as an acute febrile illness with CHIKV RNA detected in 
an acute-phase blood sample or seroconversion detected 
by CHIKV IgM/IgG ELISA in paired acute/convalescent-
phase serum samples. We tested serum samples collected 
at enrollment, 12 months, and 24 months for neutralizing 
antibodies by using a CHIKV plaque-reduction neutral-
ization test. Persons identified during active surveillance 
who had a >4-fold rise in neutralizing antibody titers in 
the absence of symptomatic chikungunya were considered 
to have subclinical infection. As reported previously (8), 
the overall incidence of CHIKV infection during the first 
year of surveillance was 12.32/100 person-years among 
all cohort members and 16.9/100 person-years among im-
munologically naive members (defined by the absence of 
CHIKV neutralizing antibodies at baseline) (Table). Only 
19% of infections were symptomatic, and most were ac-
companied by reported or documented fever without severe 
joint symptoms. Persons with detectable neutralizing anti-
bodies at the beginning of the surveillance period exhibited 
no clinical or serologic evidence of CHIKV infection dur-
ing active surveillance.
During the second year of surveillance, 765 cohort 
members completed all study activities, including un-
dergoing collection of blood samples at the beginning of 
the study and at the end of the first and second year. The 
overall incidence of CHIKV infection during the second 
year (2.84 cases/100 person-years) decreased significantly 
(p<0.05) compared with the first year (12.32 cases/100 per-
son-years). This change was attributable primarily to a de-
cline in subclinical infections and was observed equally in 
all age groups. We also observed a decline in incidence of 
symptomatic infections; however, this difference was not 
significant, possibly because of the small number of symp-
tomatic cases. The decline in incidence during the second 
year was also observed when chikungunya–immunologi-
cally naive persons were analyzed separately. The preva-
lence of neutralizing antibodies increased significantly 
from 28% at the beginning of the first year to 42% at the 
beginning of the second year. No persons with detectable 
baseline neutralizing antibodies were infected during the 
2-year surveillance period.
Our study documented the resolution of a chikungu-
nya outbreak in a prospective cohort in an endemic setting 
during 2 years of active surveillance. The duration of this 
outbreak is consistent with a previous model suggesting 
that chikungunya outbreaks in the Philippines last ≈1–3 
years (9). The decline in incidence during the second 
year coincided with an increase in chikungunya-immune 
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persons at the beginning of the second year, which ap-
proached 50%. This seroprevalence rate is higher than 
the 10%–30% rate reported after major chikungunya 
outbreaks on the island of Mayotte in the Indian Ocean, 
on the island of St. Martin in the Caribbean, and in Italy 
(5,6,10). The higher sensitivity of the neutralization assay 
in this study compared with the IgM/IgG ELISA used in 
other studies might have contributed to the higher rate of 
detection of chikungunya-immune persons. Neutralizing 
antibodies against chikungunya appear to be long lasting, 
as indicated by the higher seroprevalence in the older age 
group in our cohort. A study in Thailand demonstrated the 
presence of neutralizing antibodies more than a decade 
after infection (1). Although other environmental factors 
might contribute to outbreak resolution, the absence of in-
fection in cohort members with baseline neutralizing anti-
bodies in our study suggests the protective role of antibod-
ies. A high prevalence of neutralizing antibodies has been 
documented in a community without any previously re-
ported outbreaks (1), suggesting that immunity elicited by 
subclinical or mildly symptomatic infections might play a 
role in conferring protection against further transmission, 
leading to resolution of an outbreak.
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Table. Incidence of subclinical and symptomatic chikungunya virus infection during 2 years of active surveillance in an age-stratified 
cohort, Cebu, Philippines, 2012–2014* 
Cohort 
No. persons/prevalence 
of neutralizing antibodies 
at beginning of year, % 
No. cases/no. cases per 100 person-years (95% CI) 
Acute symptomatic 
infections Subclinical infections All infections 
Year 1 
 All persons with paired serum samples, by age 
  6 mo–5 y 203/0.7 5/3.23 (1.23–7.08) 10/6.46 (3.23–11.47) 15/9.69 (5.66–15.59) 
  6–15 y 201/1.1 8/4.23 (1.99–7.98) 24/12.68 (8.23–18.55) 32/16.91(11/.8–23.56) 
  16–30 y 200/20.24 2/1.13 (0.23–3.63) 20/11.32 (7.13–17.4) 22/12.45 (8.02–18.51) 
  31–50 y 204/52.9 4/2.38 (0.79–5.65) 21/12.48 (7.95–18.7) 25/14.85 (9.85–21.57) 
  >50 y 200/61.06 1/0.56 (0.05–2.6) 12/6.7 (3.66–11.34) 13/7.25 (4.06–12.05) 
  All ages 1,008/28.0 20/2.3 (1.5–3.49) 87/10.02 (8.08–12.3) 107/12.32 (10.15–14.83) 
 Only persons with negative neutralizing antibodies at beginning of 1st year, by age 
  6 mo–5 y  5/3.26 (1.23–7.4) 10/6.51 (3.34–11.55) 15/9.77 (5.71–15.7) 
  6–15 y  8/4.27 (2.02–8.6) 24/12.82 (8.43–18.76) 32/17.09 (11.91–23.82) 
  16–30 y  2/1.42 (0.28–4.56) 20/14.22 (8.96–21.52) 22/15.64 (10.08–23.25) 
  31–50 y  4/5.02 (1.68–11.94) 21/26.37 (16.81–39.54) 25/31.39 (20.81–45.59) 
  >50 y  1/1.41(0.13–6.6) 12/16.98 (9.27–28.75) 13/18.39 (10.3–30.55) 
  All ages  20/3.17 (1.99–4.79) 87/13.77(11.1–16.9) 107/16.94 (13.95–20.38) 
Year 2 
 All persons with paired serum samples 
  6 mo–5 y 148/8.6 2/1.68 (0.33–5.37) 1/0.84 (0.08–3.91) 3/2.51 (0.7–6.71) 
  6–15 y 184/18.6 1/0.63 (0.06–2.93) 3/1.88 (0.52–5.03) 4/2.51 (0.84–5.97) 
  16–30 y 168/35.04 1/0.74 (0.1–5.36) 4/2.98 (1.0–7.08) 5/3.72 (1.41–8.16) 
  31–50 y 172/70.4 1/0.62 (0.06–2.87) 4/2.46 (0.82–5.85) 5/3.08 (1.17–6.74) 
  >50 y 182/69.7 1/0.61 (0.06–2.86) 3/1.84 (0.51–4.9) 4/2.45 (0.82–5.83) 
  All ages 854/42.0 6/0.81 (0.34–1.67) 15/2.03 (1.19–3.27) 21/2.84 (1.81–4.26) 
 Only persons with negative neutralizing antibodies at beginning of 2nd year, by age 
  6 mo–5 y  2/1.84 (0.37–5.89) 1/0.92 (0.08–4.28) 3/2.76 (0.76–7.35) 
  6–15 y  1/0.77 (0.07–3.6) 3/2.32 (0.64–6.18) 4/3.09 (1.03–7.35) 
  16–30 y  1/1.15 (0.1–5.36) 4/4.6 (1.54–10.94) 5/5.75 (2.18–12.6) 
  31–50 y  1/2.11 (0.19–9.82) 4/8.43 (2.82–20.03) 5/10.53 (3.99–23.09) 
  >50 y  1/2.05 (0.19–9.55) 3/6.15 (1.7–16.4) 4/8.2 (2.74–19.49) 
  All ages  6/1.42 (0.59–2.93) 15/3.56 (2.08–5.72) 21/4.98 (3.18–7.47) 
Bold indicates significantly different (p<0.05) from incidence observed among the corresponding age groups during the first year of surveillance. 
Prevalence of neutralizing antibodies at the beginning of the first year was 28% and at the beginning of the second year was 42%. 
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To the Editor: Yellow fever virus (YFV) is endemic in 
tropical and subtropical Africa and South America, and it is 
transmitted to humans and nonhuman primates through the 
bites of infected mosquitoes. The virus, a member of the 
family Flaviviridae, causes yellow fever, which in severe 
cases manifests as fulminant hemorrhagic fever. Outbreaks 
of yellow fever in humans occur mostly in the urban cycle 
of the virus, which involves its transmission through the 
bites of the day-feeding infected Aedes aegypti mosquitoes 
(1). As many as 130,000 cases with fever and jaundice or 
hemorrhage may occur annually with a concomitant 78,000 
deaths (2). A low capacity for yellow fever diagnosis and 
lack of surveillance in disease-endemic countries likely 
contribute to case underreporting (1).
Although wide-scale yellow fever vaccination, which 
began in the 1940s and continued through 1960, resulted 
in a dramatic decrease in the number of outbreaks, waning 
population immunity and lapse of continued high coverage 
vaccination in yellow fever–endemic countries have led to 
the disease’s resurgence in Africa (1–3). Between 1980 and 
2012, the World Health Organization received reports of 150 
outbreaks in 26 countries in Africa (2). In the past 5 years 
(2011–2016), outbreaks have been documented in Demo-
cratic Republic of Congo, Sudan, Cameroon, Chad, Senegal, 
Côte d’Ivoire, Uganda, and Sierra Leone (3). During 2005–
2016, Sudan was the most affected country; 3 outbreaks were 
reported, resulting in 1,508 cases and 368 deaths (3,4).
Yellow fever was first recognized in Angola in the 
1930s, but not until 1971 (65 cases) and 1988 (37 cases) were 
sizeable outbreaks reported (5–7). As of July 1, 2016, a total 
of 3,552 suspected cases, including 875 laboratory-confirmed 
cases and 355 deaths, had been reported from all 18 provinc-
es of Angola, with most cases occurring in Luanda Province 
(8). In this account, we provide laboratory confirmation that 
the first suspected viral hemorrhagic fever cases in Angola 
were YFV infections and report preliminary sequencing data.
On January 14, 2016, we received whole blood samples 
from 3 patients who resided in Luanda, Angola, and were sus-
pected of having viral hemorrhagic fever. All were men, two 
22 and one 30 years of age. Clinical manifestations in all pa-
tients were fever, headache, nausea, and vomiting. Myalgia, 
malaise, reduced consciousness, and jaundice each occurred 
in 2 patients; abdominal pain, back pain, ecchymosis, con-
junctivitis, and bleeding gums each occurred in 1 patient. Two 
of the patients died 7 days after disease onset (online Technical 
Appendix Table, http://wwwnc.cdc.gov/EID/article/22/10/16-
0818-Techapp1.pdf). Laboratory diagnosis consisted of test-
ing for filoviruses, arenaviruses, and bunyaviruses, as well as 
for chikungunya and dengue viruses by using reverse tran-
scription PCR (RT-PCR). All results of RT-PCRs were nega-
tive. A real time RT-PCR for YFV, targeting the 5′ noncoding 
region (9), produced positive results for samples from all 3 pa-
tients. The samples were then tested by using a pan-flavivirus 
RT-PCR targeting the flavivirus NS5 gene region using prim-
ers FU1 8993F and cFD2 9258R (10). Resulting amplicons of 
expected size (266 bp) obtained from 2 of the 3 samples were 
subjected to conventional Sanger sequencing. Phylogenetic 
1854 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 10, October 2016
LETTERS
